Aficamten

Aficamten is an oral cardiac myosin inhibitor developed by Cytokinetics, sold as MYQORZO for obstructive hypertrophic cardiomyopathy. Sanofi holds the rights in Greater China. The next event is the FDA decision on Aficamten (supplemental application), on Nov 14, 2026 (source).

Also known as: MYQORZO
Company: Cytokinetics (CYTK) · Developer
How it works: Cardiac myosin inhibitor
Approved: MYQORZO for symptomatic obstructive hypertrophic cardiomyopathy in adults: United States, European Union

Development by disease

Obstructive hypertrophic cardiomyopathy	Approved
Non-obstructive hypertrophic cardiomyopathy	Phase 3

Upcoming events

Firm dates · a specific day set by the company or regulator

Next 60 days

Nov 14
in 32 days
Aficamten · FDA decision (supplemental application) · Obstructive HCM
Cytokinetics (CYTK)·Source

Past results and milestones

Aug 6, 2026
reported
Patient enrollment in the adolescent cohort of CEDAR-HCM has been completed. Source
Jun 1, 2026
MYQORZO launched successfully in Germany in June 2026, with UK approval and NICE recommendation also secured in the period. Source
Feb 24, 2026
FDA approved MYQORZO (aficamten) in December 2025 for treatment of adults with symptomatic obstructive HCM to improve functional capacity and symptoms. Source
Aug 7, 2025
MAPLE-HCM Phase 3 trial showed positive results. Aficamten demonstrated clinical benefit vs metoprolol monotherapy in symptomatic obstructive HCM with LVOT obstruction on exercise capacity. Source

Trials

ACACIA-HCM CAMELLIA-HCM CEDAR-HCM MAPLE-HCM MYQORZO

The investment thesis, what each upcoming event depends on and the competitive landscape are on the Cytokinetics page. Upcoming FDA decisions · All drugs